Performance Review
Looking back at the watch list from March 2016, we can see that the first five stocks managed to eke out a modest gain of +6.33%. This subset performance was severely below the Nasdaq 100 Index increase of +20.44%, in the same period of time.
symbol | name | 1-yr % chg |
ESRX | Express Scripts | -4.21% |
CERN | Cerner Corporation | 14.90% |
BIIB | Biogen Inc. | 7.44% |
VRTX | Vertex Pharmaceuticals | 11.28% |
REGN | Regeneron Pharmaceuticals | 2.24% |
When viewed from the perspective of the analysts (in blue), we see that the estimates for the coming year (at the time) were far short of the actual performance (in red) in the stock price as represented below.
According to Yahoo!Finance, there are seven analysts that track QVC Group (QVCA) are included in their analyst estimates. It is worth considering, for additional research, finding the analyst(s) who were best able to call QVC Group (QVCA). Additionally, the same analyst(s) have a low expectation of $1.02 earnings and a high of $1.71 in earnings for the coming year, putting the stock price in a range of $20.40 to $34.20. We believe that the analysts for QVCA have a good beat on this stock, let’s see if the same performance follows in the coming year.
Nasdaq 100 Watch List
Below is the watch list for March 2017 and the earnings estimates with the price projection based on those estimates as well as a strong interest stock.